Compare Adaptive Biotechnologies Corp (ADPT) vs Wendys Co (WEN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Wendys Co — how do they compare? Adaptive Biotechnologies Corp trades at $20.11 (market cap $3.33B), while Wendys Co trades at $7.4 (market cap $1.48B). The key difference: Adaptive Biotechnologies Corp is far larger — about 2.3× Wendys Co's market cap, and Wendys Co pays a 7.2% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | WEN | |
|---|---|---|
Market Cap | $3.33B | $1.48B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $11.33 |
52-Week Low | $10.24 | $6.17 |
Enterprise Value | $3.19B | $5.30B |
Dividend Yield | — | 7.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Wendy's (WEN) trades at $7.78, down 9.53% today but up significantly from recent lows amid retail-driven momentum. The stock shows strong valuation metrics with P/E of 10.26 and P/S of 0.69, while recent earnings have consistently beaten expectations. Technical indicators suggest a bullish trend with key support at $7 and resistance at $8-9 levels. Recent news highlights digital sales growth and China expansion plans as potential catalysts.
The outlook remains mixed with fundamental challenges including declining net income margins (6.77% in 2025) and negative cash flow trends offset by attractive valuation and dividend yield. Key risks include weak U.S. traffic and cost inflation, while opportunities lie in international expansion and digital initiatives. Analyst consensus leans cautious with 65% hold ratings despite recent momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
